Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Relebactam

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Merck defends antibiotic's approval from 2019
    Merck defends antibiotic's approval from 2019

    17 May 2023

    // Zachary Brennan ENDPTS

    https://endpts.com/merck-defends-antibiotics-approval-from-2019-as-bmj-investigation-points-to-decline-in-fda-standards/

    Zachary Brennan ENDPTS
    17 May 2023
    Share Share
    FDA approvals roundup: Recarbrio
    FDA approvals roundup: Recarbrio

    10 Jun 2020

    // Renee Matthews RAPS

    https://www.raps.org/news-and-articles/news-articles/2020/6/fda-approvals-roundup-recarbrio

    Renee Matthews RAPS
    10 Jun 2020
    Share Share
    US FDA approves Recarbrio to treat hospital-acquired bacterial pneumonia
    US FDA approves Recarbrio to treat hospital-acquired bacterial pneumonia

    07 Jun 2020

    // PHARMABIZ

    http://pharmabiz.com/NewsDetails.aspx?aid=126651&sid=2

    PHARMABIZ
    07 Jun 2020
    Share Share
    FDA Approves Merck’s (imipenem, cilastatin, and relebactam) for the Treatment
    FDA Approves Merck’s (imipenem, cilastatin, and relebactam) for the Treatment

    05 Jun 2020

    // MERCK

    https://investors.merck.com/news/press-release-details/2020/FDA-Approves-Mercks-RECARBRIO-imipenem-cilastatin-and-relebactam-for-the-Treatment-of-Adults-with-Hospital-Acquired-and-Ventilator-Associated-Bacterial-Pneumonia-HABPVABP/default.aspx

    MERCK
    05 Jun 2020
    Share Share
    Results of Ph 3 Trial Evaluating the Efficacy and Safety of Merck’s RECARBRIO™
    Results of Ph 3 Trial Evaluating the Efficacy and Safety of Merck’s RECARBRIO™

    06 May 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200506005158/en

    BUSINESSWIRE
    06 May 2020
    Share Share
    Results of Ph3 Trial Evaluating the Efficacy and Safety of Merck’s RECARBRIO™
    Results of Ph3 Trial Evaluating the Efficacy and Safety of Merck’s RECARBRIO™

    05 May 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200506005158/en/Results-Phase-3-Trial-Evaluating-Efficacy-Safety

    BUSINESSWIRE
    05 May 2020
    Share Share